The Liberty Capital Management Inc. Invests $2703000 in Celgene Corp. (CELG)

Meiji Yasuda Asset Management Co Ltd.'s holdings in Celgene Corporation were worth $5,834,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Baldwin Investment Mngmt Limited Liability Corp reported 1.02% in Celgene Corporation (NASDAQ:CELG). Pitcairn Co. now owns 4,948 shares of the biopharmaceutical company's stock valued at $488,000 after buying an additional 38 shares during the period. Capital Counsel LLC NY lifted its position in shares of Celgene Corporation by 0.4% in the second quarter. Advisors Asset Management Inc. lifted its position in Celgene Corporation by 6.6% in the 1st quarter. Following the completion of the sale, the director now directly owns 9,250 shares of the company's stock, valued at approximately $1,286,027.50. The stock is now trading -31.05% away from the 52-week high and separated 7.33% from the 52-week low. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company's stock valued at $250,000 after acquiring an additional 11 shares in the last quarter. Guggenheim assumed coverage on Celgene Corporation in a report on Monday, October 23rd. Herald Investment Management Ltd who had been investing in Silicon Motion Technology Corp for a number of months, seems to be less bullish one the $1.70B market cap company. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The institutional investor owned 44,920 shares of the biopharmaceutical company's stock after purchasing an additional 1,295 shares during the quarter.

Tracking other technical indicators, the 14-day RSI is presently standing at 19.78, the 7-day sits at 20.32, and the 3-day is resting at 36.85 for Celgene Corp (CELG). The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. The stock of Celgene Corporation (NASDAQ:CELG) earned "Neutral" rating by Citigroup on Friday, October 27. The firm's quarterly revenue was up 10.2% compared to the same quarter previous year. Rational Advisors LLC purchased a new position in shares of Celgene Corporation in the 2nd quarter valued at $156,000. Wells Fargo & Company cut Celgene Corporation from an outperform rating to a market perform rating in a report on Thursday, October 26th. UBS AG downgraded Celgene Corporation from a strong-buy rating to a market perform rating and set a $160.00 price objective for the company.in a research report on Thursday, October 26th. Robert W. Baird reiterated a "buy" rating and set a $162.00 price objective on shares of Celgene Corporation in a report on Thursday, September 21st. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of "Buy" and a consensus price target of $139.64.

COPYRIGHT VIOLATION NOTICE: This article was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. The 14-day ADX for Celgene Corp (CELG) is now at 54.40. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of USA & worldwide trademark & copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/06/fagan-associates-inc-grows-holdings-in-celgene-corporation-celg.html.

In related news, insider Terrie Curran sold 1,727 shares of the business's stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 13 shares in the last quarter.

Relacionada:

Comentarios


Otras noticias